<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00752843</url>
  </required_header>
  <id_info>
    <org_study_id>C-1073-16</org_study_id>
    <nct_id>NCT00752843</nct_id>
  </id_info>
  <brief_title>A Phase I Study to Determine the Effect of Mifepristone on the Pharmacokinetics of Fluvastatin in Healthy Volunteers</brief_title>
  <official_title>A Phase I, Open-Label, Fixed-Sequence Study to Determine the Effect of Single and Multiple Oral Doses of CORLUX (TM) (Mifepristone) on the Pharmacokinetics of a Single Oral Dose of Fluvastatin (a CYP2C9 Probe) in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Corcept Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Corcept Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to determine the effect of single and multiple oral doses of mifepristone on&#xD;
      the pharmacokinetics of a single oral dose of fluvastatin administered to healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a fixed-sequence, drug-drug interaction study in healthy volunteers lasting up to a&#xD;
      total of 9 weeks: up to 4 weeks screening, approximately 2 weeks for dosing (including a&#xD;
      1-week washout between periods), and approximately 3 weeks of a drug-free interval until&#xD;
      termination. The purpose of this study is to determine the effect of single and multiple oral&#xD;
      doses of CORLUX on the pharmacokinetics of a single oral dose of fluvastatin administered to&#xD;
      healthy volunteers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the effect of single and multiple oral doses of CORLUX on the pharmacokinetics of a single oral dose of fluvastatin administered to healthy volunteers.</measure>
    <time_frame>8, 9, 12, 13, 14, &amp; 15 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mifepristone + fluvastatin</intervention_name>
    <description>Subjects will receive a single oral dose of 40 mg PO of fluvastatin on three occasions: alone (Day 1), at the same time as a single dose of CORLUX 1200 mg (Day 8) and during concomitant administration of CORLUX 1200 mg/day (CORLUX on Days 8-14, fluvastatin on Day 14).</description>
    <arm_group_label>1</arm_group_label>
    <other_name>CORLUX + Lescol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female healthy volunteers&#xD;
&#xD;
          -  Body mass index (BMI) of 18-32 kg/m2&#xD;
&#xD;
          -  Female subjects must have a negative serum pregnancy test result prior to entry into&#xD;
             the study&#xD;
&#xD;
          -  All female subjects must not be of child-bearing potential&#xD;
&#xD;
          -  All male subjects with female partners of childbearing potential must consent to use a&#xD;
             medically acceptable double-barrier method of contraception and not donate sperm&#xD;
             throughout the study period and for at least 3 months (90 days) after the last dose of&#xD;
             study medication&#xD;
&#xD;
          -  The subject agrees to abstain from grapefruit or grapefruit juice for at least 2 weeks&#xD;
             prior to the first dose and until completion of the pharmacokinetic sampling (Day 15)&#xD;
&#xD;
          -  The subject must be able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any acute or chronic disease state, including but not limited to cardiovascular,&#xD;
             dermatological, endocrine, gastrointestinal, hepatic, pulmonary, and renal conditions&#xD;
             determined to be clinically significant by the Investigator&#xD;
&#xD;
          -  Any clinically significant abnormal clinical laboratory tests as determined by the&#xD;
             Investigator&#xD;
&#xD;
          -  Any concomitant medications (including prescription, over-the-counter or illicit)&#xD;
             within either 30 days or five half-lives (whichever is shorter) prior to dosing&#xD;
&#xD;
          -  Positive urine drug screen for any illicit drugs&#xD;
&#xD;
          -  Use of tobacco or any nicotine-containing products during the previous three months&#xD;
&#xD;
          -  Grapefruit juice within two weeks prior to first dose&#xD;
&#xD;
          -  Participation in a clinical investigation of any drug, biological or other&#xD;
             investigational therapy within 30 days prior to dosing&#xD;
&#xD;
          -  Signs and/or symptoms such as orthostatic hypotension, fatigue, anorexia, nausea,&#xD;
             abdominal pain, joint and muscle pain if considered to be a marker of adrenal&#xD;
             insufficiency&#xD;
&#xD;
          -  History of an allergic reaction to mifepristone or fluvastatin&#xD;
&#xD;
          -  Positive serum test for human immunodeficiency virus (HIV), hepatitis B virus or&#xD;
             hepatitis C virus&#xD;
&#xD;
          -  Blood donation within 30 days of dosing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis Swearingen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MDS Pharma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thaddeus Block, MD</last_name>
    <role>Study Director</role>
    <affiliation>Corcept Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MDS Pharma</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.corcept.com</url>
    <description>Corcept Therapeutics</description>
  </link>
  <link>
    <url>http://www.mdsps.com</url>
    <description>MDS Pharma</description>
  </link>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>September 12, 2008</study_first_submitted>
  <study_first_submitted_qc>September 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2008</study_first_posted>
  <last_update_submitted>February 15, 2012</last_update_submitted>
  <last_update_submitted_qc>February 15, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mifepristone</keyword>
  <keyword>CORLUX</keyword>
  <keyword>fluvastatin</keyword>
  <keyword>Lescol</keyword>
  <keyword>drug-drug interaction</keyword>
  <keyword>DDI</keyword>
  <keyword>pharmacokinetics</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mifepristone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

